

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 February 2002 (21.02.2002)

PCT

(10) International Publication Number
WO 02/14488 A1

(51) International Patent Classification⁷: **C12N 15/00**

(21) International Application Number: PCT/KR00/00809

(22) International Filing Date: 26 July 2000 (26.07.2000)

(25) Filing Language: Korean

(26) Publication Language: English

(71) Applicants (for all designated States except US): **CHUNG, Kwang-Hoe** [KR/KR]; 101-1305 Mooakcheonggu Apartment, Hongje-dong, Seodaemoon-gu, Seoul 120-090 (KR). **KIM, Doo-Sik** [KR/KR]; 84-3 Yeonhee-dong, Seodaemoon-gu, Seoul 120-110 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HONG, Sung-Yu** [KR/KR]; 106-501 Hansung 1-cha Apartment, 380 Googal-ri, Giheung-eup, Yongin-shi, Kyunggi-do 449-900 (KR). **KOH, You-Seok** [KR/KR]; 156-4 Sangdo 2-dong, Dongjak-gu, Seoul 156-032 (KR). **SOHN, Young-Doug** [KR/KR]; 102-902 Hyundai Apartment, 700-1 Poong-dukcheon-ri, Sooji-eup, Yongin-shi, Kyunggi-do 449-840

(KR). **YOU, Weon-Kyoo** [KR/KR]; 156-5 Yeonhee 2-dong, Seodaemoon-gu, Seoul 120-112 (KR). **JANG, Yang-Soo** [KR/KR]; 602-705 Ssangyong Apartment, 77 Soonae-dong, Bundang-gu, Seongnam-shi, Kyunggi-do 463-020 (KR). **HUH, Chin-Kyu** [KR/KR]; 8-303 Geon-duk Villa, 166 Googi-dong, Jongro-gu, Seoul 110-011 (KR).

(74) Agent: **LEE, Han-Young**; 8th Fl., Seowon Bldg., 1675-1 Seocho-dong, Seocho-gu, Seoul 137-070 (KR).

(81) Designated States (national): AU, CN, JP, KR, US.


(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published:

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL PROTEIN DERIVED FROM AGKISTRODON SAXATILIS EMELIANOV AND PROCESS FOR PREPARING THE SAME



WO 02/14488 A1

(57) **Abstract:** The present invention relates to Saxatilin, a protein derived from the venom of a Korean snake, *Agkistrodon saxatilis emelianov*, a process for preparing Saxatilin, and pharmaceutical application of the same as anti-platelet aggregation agent and anti-tumor agent. The present inventors purified Saxatilin from the venom of *Agkistrodon saxatilis emelianov*, cloned its cDNA, and prepared recombinant Saxatilin by culturing a microorganism transformed with an expression vector containing the cDNA. Saxatilin effectively suppresses the platelet aggregation and angiogenesis of tumor cells, which makes possible its practical application as an active ingredient of anti-platelet agent and anti-tumor agent.

NOVEL PROTEIN DERIVED FROM AGKISTRODON SAXATILIS EMELIANOV
AND PROCESS FOR PREPARING THE SAME

5 BACKGROUND OF THE INVENTION

Field of the Invention

10 The present invention relates to Saxatilin, a protein derived from a Korean snake, *Agkistrodon saxatilis emelianov*, a process for preparing Saxatilin, and pharmaceutical application of the same, more specifically, to Saxatilin, a protein derived from the venom of a Korean snake, *Agkistrodon saxatilis emelianov*, a process for 15 preparing Saxatilin, and pharmaceutical application of the same as anti-platelet aggregation agent and anti-tumor agent.

20 Description of the Prior Art

25 Tumor invasion and metastasis are defined as the proliferating stages of the tumor cells at whole body from the primary tumor, which finally persuade patient into death. Cancer cells detached from the primary malignant neoplasm(mostly endothelium) penetrate the basement membrane which separates the cancer cells from the other tissue. As some penetrated cells can invade not only endothelium but also basement membrane which surrounds the blood vessels, they can migrate freely via blood vessels 30 and finally set down on capillary vessels. If cancer cells penetrate capillary vessels again, they can form secondary tumor. The probability of secondary tumor formation from the primary tumor followed by dissemination and invasion is under one in ten thousand(see: Erkki R., Scientific 35 American, 257:72-77(1996)).

The interaction of cell and extracellular matrix (ECM) is required for the tumor invasion and metastasis.

During metastasis, tumor cells induce endothelial cell death, leading to exposure of basement membrane, which facilitates adhesion of tumor cells with ECM protein in surrounding stroma(see: Hynes, R. O., *Cell*, 48:549(1987)).
5 These substrate proteins promote cell adhesion by binding with cell surface receptor including integrin family.

In terms of structure, each integrin is a heterodimer formed by α subunit and β subunit via non-covalent binding. It has been reported that $\beta 1$ subfamily plays a role in cell-cell interaction directly as well as in cell-ECM substrate adhesion as a major contact mediator(see: Larjava, H. et al., *J. Cell. Biol.*, 110:803-815(1990)). $\beta 2$ subfamily distributed in leukocyte includes cell surface receptors which mediate cell-cell interaction.
10 $\beta 3$ subfamily including vitronectin receptor and thrombocyte glycoprotein IIb/IIIa complex may be able to function in the development of tumor invasiveness and in the progress of tumor into the malignant tumor(see: Albelda, S. M. et al., *Cancer Res.*, 50:6757-6764(1990)).
15

20 The integrin receptor complex that spans transversely cell membrane plays a role in connecting cytoskeletal network with extracellular matrix. The core sequences, common to cell-adhesion molecules like fibrinogen, vitronectin and laminin are known to be responsible for cell adhesion, spread and integration. By the way, it is also suggested that cancer promotion and metastasis can be closely related to the role of integrin(see: Giancotti, F. G. and Rouslahti, E., *Cell*, 60:849-859(1990); Hynes, R. O., *Cell*, 69:11-25(1992); Nip, J. et al., *J. Clin. Invest.*, 96:2096-2103(1995)). Over-expression of fibronectin receptor $\alpha 5\beta 1$ is known to diminish a mutated phenotype in CHO(Chinese hamster ovary) and decrease in the expression level of integrin $\alpha 5\beta 1$ in the rodents cells which are mutated into ras(see: Plantefaben, L. C. and Hynes, R. O., *Cell*, 56:281-290(1989)). Super-fibronectin, a fibronectin polymer, has been reported to prevent cancer promotion and metastasis(see: Pasqualini, R. et al., *Nature Medicine*,
25
30
35

2:1197-1203(1996)).

Integrin $\alpha V\beta 3$ can be useful as a marker of most malignant tumor cells, which shows the function of integrin in the development of malignant human melanoma(see: Albelda, S. M. et al., *Cancer Res.*, 50:6757-6764(1990)). The expression and adhesive phenotype of integrin αV gene have a direct correlation with *in vivo* proliferation of human melanoma(see: Felding-Habermann, J. *Clin. Invest.*, 89:2018-2022(1992)).

Meanwhile, angiogenesis is the process of new blood vessels formation by sprouting of new vessels from existing blood vessels(see: Folkman, J. and D'Amore, P. A., *Cell*, 87:1153-1155(1996)). Angiogenesis occurs during development, wound healing and inflammation, and is the essential process in the tumor growth. Cell-adhesion molecules regulate angiogenesis in smooth muscle cells and capillary endothelial cells(see: Nguyen, M. et al., *Nature*, 365:267 (1993)).

The turnover of tumor angiogenesis is determined by the balance change between stimulating and inhibiting regulators. In relation to this, two cytokine-dependent pathways of angiogenesis have existed and are distinguished by the distinct vascular cell integrins, $\alpha V\beta 3$ and $\alpha V\beta 5$. These two integrins are expressed in newly formed blood vessels and play an important role in angiogenesis stimulated by bFGF(basic fibroblast growth factor), TNF- α (tumor necrosis factor- α), VEGF(vascular endothelial growth factor) and fragments of human tumors(see: Friedlander, M. et al., *Science*, 270:1500-1502(1995)). The activation of $\alpha V\beta 3$ integrin stimulates a survival signal inducing the vessel proliferation and differentiation, which demonstrates that the signal transmission by cytokine and integrin receptor is related to angiogenesis(see: Brooks, P. C. et al., *Cell*, 79:1157-1164(1994)).

Disintegrins, which are known to be potent antagonists of integrin, are small proteins derived from the snake venom(see: Niewiarowski, S. et al., *Semin.*

Hematol., 31:289-300(1994)). Most of disintegrins contain Arg-Gly-Asp(GRD) or Lys-Gly-Asp(KGD) motifs recognized by thrombocyte fibrinogen receptor, $\alpha 2b\beta 3$. It is reported that disintegrins containing RGD sequences inhibit adhesion of integrin-mediated metastatic cells with ECM and finally block metastasis(see: Trikha, M. et al., Cancer Res., 54 (8):4993-4998(1994)). Integrin $\alpha V\beta 3$ has been identified as a marker of angiogenic vessel in chicken embryo and human cells(see: Brooks, P. C. et al., Science, 264:569-571 (1994)). Monoclonal antibody of integrin $\alpha V\beta 3$ disrupts angiogenesis by inducing apoptosis of the newly formed vascular endothelial cells. Synthesized peptides containing RGD sequence, which is known to prevent integrin $\alpha V\beta 3$ from binding with ligands, inhibit a tumor-induced angiogenesis (see: Brooks, P. C. et al., Cell, 79:1157-1164(1994)) of CAM(chick chorioallantoic membrane). Furthermore, Angiogenin, which is known to help adhesion and proliferation of endothelial cell as a subsidiary factor, is also inhibited by synthesized RGD peptides. Recently, the snake venom-derived disintegrin, Triflavin is reported to inhibit TNF- α stimulated angiogenesis. These results provide the possibility that disintegrins, synthesized RGD peptides and anti- $\alpha V\beta 3$ monoclonal antibodies, may be developed as anti-cancer drugs.

On the other hand, the snake venom is known to contain various kinds of proteins that affect thrombosis and hemostasis. Since thrombus formation resulted from the abnormal platelet coagulation raises lethal thrombosis, platelet aggregation antagonist or agonist was isolated from the snake venom and identified. As for aggregation mechanism, platelet aggregation is mediated by fibrinogen binding with a glycoprotein in the platelet of GP IIb/IIIa receptor, where the amino acid sequence of Arg-Gly-Asp(RGD) of fibrinogen binding site has been reported to be crucial for fibrinogen binding with GP IIb/IIIa receptor(see: Rouslagt E. and Pierschbacher M. D., Science, 238:491-497(1987)). Therefore, proteins containing the said

sequence competitively inhibit fibrinogen binding with GP IIb/IIIa receptor which leads to the suppression of platelet aggregation. At first, inhibitors of GP IIb/IIIa receptor isolated from the snake venom were small proteins of 5 kD to 9 kD(see: Huang, T. F. et al., *J. Biol. Chem.*, 262:16157-16163(1987)). Afterwards, various kinds of platelet aggregation inhibitors, which included large molecular weight antagonists, were isolated from the snake venom. These inhibitors are rich in cysteins, and common in binding with GP IIb/IIIa receptor by the interaction with the Arg-Gly-Asp(RGD) amino acid sequence. In addition, the structures of Kistrin(see: Alder, M. et al., *Science*, 253:445-448(1991); Alder, M. et al., *Biochemistry*, 32: 282-289(1993)), Flavoridine(see: Klaus, W. et al., *J. Mol. Biol.*, 232:897-906(1993); Senn, H. and Klaus, W., *J. Mol. Biol.*, 232:907-925(1993)), Albolabrin(see: Jaseja, M. et al., *Eur. J. Biochem.*, 218: 853-860(1993)) and Echistatin(see: Chen, Y. et al., *Biochemistry*, 30:11625-11636(1991); Cooke, R. M. et al., *Eur. J. Biochem.*, 202:323-328(1991); Cooke, R. M. et al., *Protein Eng.*, 5:473-477(1992); Saudek, V. et al., *Biochemistry*, 30:7369-7372(1991); Dalvit, C. et al., *Eur. J. Biochem.*, 202:315-321(1991)) have been identified by nuclear magnetic resonance(NMR) spectroscopy. And, the inhibition of fibrinogen binding with GP IIb/IIIa receptor by these antagonists was ascertained by using animal model(see: Collen, B. S., *J. Clin. Invest.*, 76:101-108(1985); Gold, H. K. et al., *Circulation*, 77:670-677(1988); Yasuda, T. et al., *J. Clin. Invest.*, 81:1284-1291(1988); Coller, B. S. et al., *Blood*, 68:783-786(1986); Hanson, S. R. et al., *J. Clin. Invest.*, 81:149-158(1988)).

In relation to this, extensive studies have been made on the venom of *Agkistrodon halys brevicaudus* or *Caliginosus*. Salmosin derived from the venom of *Agkistrodon halys brevicaudus*, a protein of about 7.5 kD, has been proposed as a potent platelet aggregation inhibitor(see: Korean Patent No. 142606). However, little

is known about the venom of *Agkistrodon saxatilis emelianov* because of the rareness of *Agkistrodon saxatilis emelianov* compared with other snakes. This invention was made on the assumption that the potent toxicity and high lethality of 5 *Agkistrodon saxatilis emelianov* venom may be closely related with the bleeding.

SUMMARY OF THE INVENTION

10 The present inventors examined the existence of a protein which plays a role as platelet aggregation inhibitor from the venom of a Korean snake, *Agkistrodon saxatilis emelianov*, and discovered a novel protein, Saxatilin. Then, a microorganism transformed with a 15 recombinant expression vector comprising Saxatilin cDNA was prepared to manufacture recombinant Saxatilin from yeast cell in large scale. In addition, the inventors found that the recombinant Saxatilin possesses an inhibitory activity against platelet aggregation and angiogenesis which is 20 essential for the metastasis and proliferation of tumor, without any untoward effect on normal endothelial cell proliferation, assuring that the said protein can be developed as an anti-tumor agent.

25 The first object of the present invention is, therefore, to provide Saxatilin derived from the venom of a Korean snake, *Agkistrodon saxatilis emelianov*.

The second object of the invention is to provide cDNA encoding Saxatilin.

30 The third object of the invention is to provide amino acid sequence of Saxatilin deduced from the cDNA.

The fourth object of the invention is to provide a recombinant expression vector, which produces Saxatilin in yeast cell.

35 The fifth object of the invention is to provide a recombinant microorganism transformed with the recombinant expression vector.

The sixth object of the invention is to provide a process for preparing recombinant Saxatilin from the transformed microorganism.

5 The seventh object of the invention is to provide an anti-platelet aggregation agent comprising Saxatilin.

The eighth object of the invention is to provide an anti-tumor agent comprising Saxatilin.

BRIEF DESCRIPTION OF THE DRAWINGS

10

The above, the other objects and features of the invention will become apparent from the following descriptions given in conjunction with the accompanying drawings, in which:

15

Figure 1 is a graph showing the inhibitory activity of Saxatilin compared with those of known platelet aggregation inhibitors.

20

Figure 2 is a gene map of recombinant Saxatilin expression vector, pPSAX.

Figure 3 is a graph showing the effect of recombinant Saxatilin on HUVEC growth compared with that of Salmosin.

25

Figure 4a is a graph showing the effect of anti- $\alpha V\beta 3$ monoclonal antibody, GRGDSP, GRGETP and recombinant Saxatilin on the binding of Vitronectin to HUVEC.

30

Figure 4b is a graph showing the effect of anti- $\alpha V\beta 3$ monoclonal antibody, GRGDSP, GRGETP and recombinant Saxatilin on the binding of Saxatilin to HUVEC.

Figure 5a is a photograph showing the bFGF-stimulated angiogenesis of the CAM(chick chorioallantoic membrane).

Figure 5b is a photograph showing the effect of recombinant Saxatilin on CAM angiogenesis.

Figure 6a is a photograph showing the normal lung tissue without Lewis lung cancer cells.

35

Figure 6b is a photograph showing the lung tissue injected with Lewis lung cancer cells and treated with PBS control.

Figure 6c is a photograph showing the lung tissue injected with Lewis lung cancer cells and treated with recombinant Saxatilin.

5 DETAILED DESCRIPTION OF THE INVENTION

10 The present inventors isolated Saxatilin from the venom of a Korean snake, *Agkistrodon saxatilis emelianov* and cloned cDNA encoding Saxatilin, a recombinant expression vector comprising the cDNA, and a recombinant microorganism transformed with the recombinant expression vector, and manufactured recombinant Saxatilin by culturing the transformant.

15 The method of isolating Saxatilin from *Agkistrodon saxatilis emelianov* and the process for preparing recombinant Saxatilin are illustrated in more detail as follows.

20 The venom of *Agkistrodon saxatilis emelianov* was collected and purified by using gel-filtration column and reverse-phase HPLC, to obtain a protein possessing platelet aggregation inhibitory activity. Determination of amino acid sequence of the protein revealed that it is a novel protein and it was designated as Saxatilin. The inventors cloned cDNA encoding Saxatilin from cDNA library derived from the venom of *Agkistrodon saxatilis emelianov*. The Saxatilin cDNA was designed to contain both *Xho I* restriction site and protease KEX2 recognition site at N-terminal region and introduced into the *EcoR I/Xho I* site at C-terminal region of α -factor secretory signal protein of an expression vector, pPIC9(8.0 kb). The expression vector encoding Saxatilin was designated as pPSAX. The expression vector may be transformed into yeast cells of *Pichia* sp., *Hansenula* sp. and *Saccharomyces* sp., preferably *Pichia* sp. such as *Pichia pastoris* GS115, SMD 1168 and KM71.

25 30 35

The constructed pPSAX was transformed into *Pichia*

5 *pastoris* GS115 and the transformed cell was designated as "Pichia pastoris Y/pPSAX(*Pichia pastoris* Y/pPSAX)", and deposited with the Korean Culture Center of Microorganisms (KCCM, Hongje-1-dong 361-221, Seodaemun-gu, Seoul, Korea), an international depository authority on July 21, 2000 as accession No. KCCM-10201.

10 The process for preparing recombinant Saxatilin comprises a step of culturing the transformed microorganism to obtain recombinant Saxatilin: The transformed cells were inoculated in the minimum glycerol media and incubated until 1.0 O.D₆₀₀ unit, harvested by centrifugation, and resuspended in the minimum methanol media and cultured in a fed-batch wise. The minimum glycerol media (pH 6.0) contained 0.5 to 1.5% of yeast extract or peptone as 15 nitrogen source, 0.5 to 2.5% of glycerol, dextrose or glucose as carbon source and trace amounts of biotin. The minimum methanol media was the minimum glycerol media with 0.1 to 1.0% (v/v), preferably 0.3 to 0.8% (v/v), most preferably 0.5% (v/v) of methanol as carbon source. During 20 the cell incubation in minimum glycerol media, the temperature condition was 25 to 35 °C, preferably 28 to 32 °C, most preferably 30 °C, for 12 to 24 hr, preferably 16 to 20 hr, most preferably 18 hr. During the cell incubation in the minimum methanol media, the temperature 25 condition was 25 to 35 °C, preferably 28 to 32 °C, most preferably 30 °C, for 72 to 120 hr, preferably 84 to 108 hr, more preferably 96 hr.

30 For the purification of recombinant Saxatilin, the supernatant obtained from the cell broth by the centrifugation was applied to a hydrophobic column and HPLC, where the hydrophobic column was charged with phenyl Sepharose resin, and preferably eluted with 0.5 to 2M ammonium sulfate solution, and HPLC was equipped with source 30 RPC column and preferably eluted with 0.01 to 35 0.2% (v/v) TFA in acetonitrile.

The platelet aggregation-inhibitory activity of

recombinant Saxatilin was compared with that of a known platelet aggregation inhibitor, recombinant Salmosin. As a result, it was demonstrated that the platelet aggregation-inhibitory activity of recombinant Saxatilin was similar 5 to that of recombinant Salmosin. In addition, in case of being expressed in yeast cell, the expression efficiency of Saxatilin was superior to that of Salmosin. Comparing the amino acid sequence of recombinant Saxatilin with that of Salmosin, it was confirmed that the difference in the 49th 10 amino acid of two proteins brought about the different expression mode and efficiency in two proteins. Since the recombinant Salmosin contained the 48th and 49th Arg, it is readily susceptible to a signal peptidase existing in yeast, which recognizes the amino acid sequence of Lys and Arg, 15 while the recombinant Saxatilin with 49th Met was rarely attacked by the same enzyme. Thus, it was understood that the 49th amino acid in recombinant Saxatilin plays an important role in improving expression efficiency and stability.

20 To investigate whether Saxatilin inhibits tumor metastasis, the effect of Saxatilin on angiogenesis was determined by HUVEC(human umbilical vein endothelial cell) assay and CAM(chick chorioallantoic membrane) assay, which were developed as the model system for the study of angiogenesis. As a result, it was demonstrated that 25 Saxatilin inhibited angiogenesis induced by tumor. The inhibition of HUVEC proliferation by Saxatilin was due to the direct interaction of Saxatilin with Vitronectin receptor, $\alpha V\beta 3$ integrin, localized on the surface of HUVEC. It has been already known that disintegrin prevents tumor 30 cells from binding with endothelia, leading to suppress the colony formation of the metastatic tumor. However, little has been known whether the growth of already-invaded metastatic tumor was inhibited. In this regard, the effect 35 of Saxatilin on the metastatic tumor growth was investigated, which revealed that Saxatilin effectively inhibits the metastatic tumor growth without cytotoxicity.

The present invention is further illustrated in the following Examples, which should not be taken to limit the scope of the invention.

5

Example 1: Purification of Saxatilin

To isolate Saxatilin from the venom of *Agkistrodon saxatilis emelianov*, 302.4 mg of crude venom from the snake 10 was applied to a Sephadex G-75 gel filtration column(1.8 x 100 cm) equilibrated with PBS buffer, and fractionated at a flow rate of 20 ml/h. The activity of Saxatilin was determined by the platelet aggregation inhibition assay: The concentrated human platelet rich plasma(PR) obtained 15 from 400 ml of human blood was diluted to the concentration of 300,000 platelets/ μ l. The diluted PR(450 μ l) was mixed with 50 μ l of PBS and then incubated in the aggregometer(Chromo-Log, USA) at 37 °C for 3 minutes. After collagen(2 nM) was added into the PR solution to 20 induce the platelet aggregation, the difference of light transmittance was measured.

The active fractions showing the inhibitory effect on the platelet aggregation contained a protein whose molecular weight ranges from 7 kD to 10 kD in Native-PAGE 25 gel. The pooled active fractions were applied to a reverse-phase HPLC(C18) column(7.8 x 300 mm) equilibrated with distilled water containing 0.1%(v/v) TFA, eluted by the linear gradient of 5-45% acetonitrile with 0.1%(v/v) TFA. Saxatilin was eluted at the point of 21% acetonitrile 30 with the purification yield of 0.2%.

Example 2: Amino acid sequence analysis of Saxatilin

To analyze the amino acid sequence of Saxatilin, the purified Saxatilin was electrophoresed on SDS-PAGE gel 35 under the reducing condition and electroblotted onto polyvinylidene difluoride(PVDF) membrane(Biorad, USA). The

N-terminal amino acid sequence of Saxitilin was determined to be GEECDCGAPANP (SEQ ID NO:9) by automated protein sequence analyzer.

5 Example 3: Determination of the molecular weight of
Saxatilin by mass spectrometer

10 The molecular weight of Saxatilin was determined as
three different forms of 7,444, 7,515 and 7,647 Da by the
aid of Mass spectrometer (Kratos Kompact Mold II, Kratos
Analytical, Manchester, U.K.), which is ascribed to three
types of isoforms containing N-terminal sequences of
'EAGEE' and 'AGEE', in addition to 'GEE'.

15 Example 4: Determination of DNA sequence encoding Saxatilin

20 For the cloning of Saxatilin cDNA, mRNA was extracted
from the venom gland of *Agkistrodon saxatilis emelianov*
using oligo-dT cellulose. cDNA library was constructed by
using a template of mRNA obtained from the venom gland, and
oligo-dT primer and reverse transcriptase. Then, 5' primer
was designed by deduction from the N-terminal sequence,
which is 5'-GGNGARGARTGYGAYTGYGG-3' (SEQ ID NO:3): primer 1.
The 3' primer was designed by deduction from the C-terminal
25 sequence, determined during subcloning process, which is
5'-GGCATGGAAGGGATTCTGG-3' (SEQ ID NO:4): primer 2. The
polymerase chain reaction (PCR) was performed using the 5'
primer, the 3' primer and a template of the synthesized
cDNA library of venom gland. The PCR products of 220 bp
30 separated on agarose gel electrophoresis were subcloned
into pGEM-T vector (Promega, USA) and used to analyze the
DNA sequence encoding Saxatilin (SEQ ID NO:2). The total
amino acid sequence of Saxatilin was deduced from the
cloned cDNA sequence (SEQ ID NO:1).

35 Example 5: Comparison of the inhibitory effect of
Saxatilin with known peptides possessing

platelet aggregation inhibitory activity

For the comparison of the inhibitory effect of Saxatilin with those of other known peptides possessing platelet aggregation inhibitory activity, Salmosin(see: Korean Patent No. 142606, SEQ ID NO:10) and GRGDSP(SEQ ID NO:7), the platelet aggregation inhibition assay was performed as follows: 225 μ l of the human platelet rich plasma(300,000 platelets/L) was mixed with 25 μ l of the platelet aggregation inhibitor peptide solutions in PBS and then incubated in aggregometer(Chromo-Log, USA) at 25 °C for 5 minutes. After ADP was added into each of the PRP solutions to induce the platelet aggregation, the turbidity was measured, respectively(see: Figure 1). In Figure 1, (●) represents the degree of platelet aggregation inhibition of Saxatilin; (○), Salmosin(SEQ ID NO:10); and (■), GRGDSP(SEQ ID NO: 7), respectively. As shown in Figure 1, IC₅₀ value of Saxatilin was 179 nM, which is comparable with 173 nM of Salmosin, and 1000 times more potent inhibitory effect than GRGDSP peptide.

Example 6: Cloning of Saxatilin DNA

The PCR(Robocycler™, Stratagene, USA) was performed using a plasmid containing Saxatilin cDNA, prepared from Example 4, as a template and the following two primers:

N-terminal primer, containing both *Xho I* restriction site and protease KEX2 recognition site,
30 5'-CCGCTCGAGAAAAGAGAGGCCGGAGAAGATGT-3' (SEQ ID NO:5).

C-terminal primer, containing both *EcoR I* restriction site and two stop codons,
5'-CGGAATTCTCATTAGGCATGGAAGGGA-3' (SEQ ID NO:6).

35 The PCR was carried out for 30 cycles of 1 min at 94 °C (denaturation), 1 min at 55 °C (annealing), and 1 min at 72 °C (polymerization), respectively. The DNA fragments

of about 250 bp, PCR products, were cloned into pBluescriptKS(2.9 kb, Stratagene, USA) by the reaction with T4 DNA ligase to construct a recombinant plasmid. The recombinant plasmid was used for the transformation of 5 *E.coli* XL-1Blue. The transformed *E.coli* was incubated on LB(Luria Botani) plate with 100 μ g/ml of ampicillin and selected by formed white colony. The plasmid extracted from the white colony was investigated using restriction map analysis and DNA sequence analysis(ALF system, Amersham 10 Pharmacia Biotech, USA), and thus confirmed that the DNA fragment of 250 bp by PCR was Saxatilin cDNA. The *EcoR I/Xho I* fragment of the plasmid was cloned into the C-terminal region of the α -factor secretory signal protein of an expression vector pPIC9(8.0kb), to give an expression 15 vector comprising Saxatilin encoding cDNA, pPSAX(8.3 kbp) (see: Figure 2).

The pPSAX was digested with *SalI* to give a linear DNA fragment and dissolved in TE buffer at a concentration of 0.5 μ g/ μ l, which was then mixed with 80 μ l of *Pichia pastoris* GS115 competent cell(Invitrogen, USA) to perform 20 transformation by electroporator(Bio-Rad Gene Pulser, USA) under a condition of 1.5 kV. The transformed cells were spread onto a histidine-deficient agar plate and incubated at 30 °C for 3 days. The selected colonies were inoculated to 1L of minimum glycerol media(100 mM sodium phosphate pH 25 6.0, yeast nitrogen base 1.34%, biotin 4x 10^{-5} %, glycerol 1%) and incubated at 30 °C until O.D₆₀₀ unit reaches to the level of 1.0. At the end of the incubation period, the cells were harvested by centrifugation at 3000 xg, and 30 resuspended in the minimum methanol media(containing 100 mM sodium phosphate pH 6.0, yeast nitrogen base 1.34%, biotin 4x 10^{-5} %, methanol 0.5%). These cells were grown at 30 °C and induced the expression of recombinant Saxatilin. The cells were further incubated for 96 hr with the addition of 35 0.5% methanol at an interval of 24 hour, and it was confirmed that Saxatilin was accumulated in the media during the incubation period. The transformed cell

5 containing Saxatilin expression vector, pPSAX, was designated as "Pichia pastoris Y/pPSAX(*Pichia pastoris* Y/pPSAX)", and deposited with the Korean Culture Center of Microorganisms (KCCM, Hongje-1-dong 361-221, Seodaemun-gu, Seoul, Korea), an international depository authority as accession No. KCCM-10201 on July 21, 2000.

10 For the purification of Saxatilin, the supernatant obtained from cell broth by the centrifugation at 5,000 xg was applied to a phenyl Sepharose column of 1.3 x 20cm(Bio-Rad, USA) equilibrated with 1.5 M ammonium sulfate solution, and eluted with 1 M ammonium sulfate solution at a flow rate of 20 ml/hour to obtain active fractions of Saxatilin. The activity of Saxatilin was determined in a similar manner as in Example 1. The active fractions were loaded 15 into HPLC column(source 30 RPC column, 7.8 x 300mm) equilibrated in distilled water with 0.1%(v/v) TFA, and eluted by the linear gradient of 0 to 50%(v/v) acetonitrile to give pure Saxatilin with a purification yield of 107 mg/L.

20

Example 7: Inhibition of platelet aggregation by recombinant Saxatilin

25 Recombinant Saxatilin obtained in Example 6 was assayed by the platelet aggregation inhibition method described in Example 1, and compared with those of wild-type Saxatilin obtained in Example 1 and GRGDSP(SEQ ID NO:7) (see: Table 1), respectively.

30 As shown in Table 1 below, the recombinant Saxatilin represented the comparable platelet aggregation inhibitory activity with the wild-type Saxatilin.

Table 1: IC₅₀ determined by platelet aggregation inhibition assay

35

Inhibitor	IC ₅₀ (nM)
Wild-type	136

Saxatilin	
Recombinant Saxatilin	139
GRGDSP (SEQ ID NO: 7)	270 x 10 ³

Example 8: Anti-platelet aggregation activity of Saxatilin

5 When a mixture of collagen and epinephrine was injected into mice intravenously, thrombus was formed in pulmonary artery, which led to paralysis, dilation of pupil, laboring breath and convulsions, and finally 70% of the mice died not more than 5 min. Thus, it was investigated
10 whether the intravenous injection of recombinant Saxatilin could reduce the thrombosis symptoms.

At 10 minutes after Saxatilin(0, 0.1, 0.25 and 0.5 mg/kg dissolved in 0.1 ml PBS, respectively) was intravenously injected into the tails of ICR mice, the mixture of collagen and epinephrine(120 µg collagen and 12 µg epinephrine in 0.1ml PBS) was also injected into the tails of ICR mice, intravenously, and the viability was determined(see: Table 2).

20 Table 2

Saxatilin (mg/kg)	0	0.1	0.25	0.5
Treatment				
Mortal group /Total group	18/20	16/20	11/20	3/20
Viability	10	20	55	85

25 As shown in Table 2, based on the results that the treatment of Saxatilin caused the increase in viability, Saxatilin was supposed to suppress the coagulation induced by collagen and epinephrine, with more potent inhibitory activity in case of pre-treatment than post-treatment.

Example 9: Effect of recombinant Saxatilin on human umbilical vein endothelial cell (HUVEC)

5 It has been known that disintegrins containing RGD sequence which is a part of recombinant Saxatilin(49-51 amino acid sequence), suppress the bFGF-stimulated endothelial cell growth. To investigate whether recombinant Saxatilin containing RGD sequence inhibits the 10 endothelial cell proliferation, proliferation inhibition assay was performed using HUVEC. The activity of Saxatilin was compared with that of Salmosin(SEQ ID NO:10), which is known to inhibit the bFGF-stimulated endothelial cell proliferation.

15 HUVEC was cultured on 24-well microplate coated with gelatin at 37 °C for 24 hr under an environment of 5% CO₂. After the media was replaced with 0.25 ml DMEM containing 5% fetal bovine serum, recombinant Saxatilin obtained from Example 6 and Salmosin were added in a concentration of 0, 20 20, and 30 µg/ml, respectively. Then, cells were further 25 incubated for 20 min and treated with 1 ng/ml of bFGF solution. After incubation of 72 hr, cells were trypsinized and the cell numbers were counted to determine cell viability(see: Figure 3). As shown in Figure 3, Saxatilin inhibited the HUVEC growth in a dose-dependent manner similarly as Salmosin.

Example 10: Inhibition of HUVEC adhesion by Saxatilin

30 To confirm that inhibition of HUVEC proliferation by Saxatilin is due to the direct interaction of Saxatilin with Vitronectin receptor, $\alpha v \beta 3$ integrin, localized on the HUVEC surface, it was investigated whether Saxatilin blocks HUVEC from binding to Vitronectin-coated 96-well plate.

35 96-well plate was coated with recombinant Saxatilin obtained in Example 6(1 µg/well) as well as Vitronectin(0.5 µg/well) which were dissolved in phosphate buffered

saline(PBS) for 16 hr at 4°C. After washing the plate, 10 mg/ml of heat-treated bovine serum albumin(BSA) was added for blocking of uncharged protein binding site. The plate was incubated for 1 hr and washed with PBS. HUVEC was 5 trypsinized and washed with PBS three times, and then, resuspended in serum-free DMEM. 5×10^4 cells were mixed with anti- $\alpha V\beta_3$ monoclonal antibody, a synthesized RGD peptide, GRGDSP(SEQ ID NO:7), a synthesized RGE peptide, GRGETP(SEQ ID NO:8) and Saxatilin, and pre-incubated for 20 min at 37°C. Then, the mixture was added to the wells of both Saxatilin and Vitronectin-coated 96-well plate. After 10 1 hr of incubation at 37°C under an environment of 5% CO₂, the plate was washed with PBS to remove unbound cells, and bound cells were fixed and stained with Coomassie blue. 15 Optical absorbences of the wells were measured at 540nm to count relative cell numbers(see: Figures 4a and 4b).

As shown in Figures 4a and 4b, pre-incubation of bFGF-stimulated HUVEC with GRGDSP(SEQ ID NO:7), Saxatilin and anti- $\alpha V\beta_3$ monoclonal antibody prevented HUVEC from 20 adhering to Vitronectin(see: Figure 4a) and Saxatilin(see: Figure 4b) as well, indicating that Saxatilin inhibited integrin-mediated cell adhesion by binding with $\alpha V\beta_3$ integrin on HUVEC surface.

25 Example 11: Effect of Saxatilin on angiogenesis by chick chorioallantoic membrane(CAM) assay

Chick chorioallantoic membrane(CAM) assay, a simulated in vivo model, was carried out to examine the 30 effect of Saxatilin on bFGF-stimulated angiogenesis. A part of the rind of fertilized 3-day-old egg was broken carefully, and sealed with transparent tape, and incubated for 10 days at 37°C under an environment of 60% humidity. Then, bFGF was applied to the chick chorioallantoic 35 membrane(CAM) of individual embryo(6 ng/embryo) to induce angiogenesis. After further incubation of 24 hr, PBS as a negative control and 5 μ g recombinant Saxatilin obtained

from Example 6 were applied to CAM, respectively. At 72 hr after treatment, the blood vessels of embryos were observed(see: Figures 5a and 5b). As shown in Figures 5a and 5b, PBS showed no effect(see: Figure 5a) while 5 Saxatilin had an inhibitory effect on angiogenesis(see: Figure 5b).

Example 12: Inhibitory effect of Saxatilin on metastatic tumor growth

10

Disintegrins suppress the lung tumor colony formation by preventing tumor cells from adhering to endothelial cells. However, it has never been reported that disintegrins inhibit the metastatic tumor promotion. 15 Therefore, it was investigated whether Saxatilin has an effect on the metastatic tumor growth.

1 x 10⁶ Lewis lung carcinoma cells(purchased from American Type Cell Culture, Rockville, Md, USA) were injected into the tails of 8-week-old male C57BL/6 20 mice(Charles river, Japan), intravenously. At 4 day after injection, recombinant Saxatilin obtained from Example 6 was periodically applied to mice by intravenous injection in an amount of 1.25 mg/kg/day(once per day). After 4-weeks of periodical treatment, tumor-bearing mice were 25 sacrificed, and the number of tumor colony was counted by using stereomicroscope. As a result, it was clearly demonstrated that Saxatilin potently inhibited the metastatic tumor growth(see: Table 3).

30 Table 3: Suppression of metastatic Lewis lung carcinoma growth by Saxatilin

Saxatilin (mg/kg mouse)	Number of tested mice	Average colony number	Inhibition rate (%)
0	4	15± 6	0
1.25	4	0.7± 0.6	95

5 The suppression of metastatic tumor growth by Saxatilin was ascribed to the anti-angiogenesis effect of Saxatilin, which potently inhibited the bFGF-stimulated BCE cell proliferation by blocking of α V β 3 integrin function essential for angiogenesis. In addition, Saxatilin showed no toxicity on tested mice.

10 Furthermore, to observe the direct effect of Saxatilin on the metastatic lung carcinoma, histochemical study was carried out. Tumor-bearing lung tissue was fixed in paraffin in accordance with the conventionally known method followed by treatment of Bouin's solution for 4 hours. The tissue section of 4 μ m thickness was infiltrated with trypsin at 37 °C for 10 min and washed with PBS. The tissue section was stained with hematoxylin 15 and eosin, and then mounted(see: Figures 6a, 6b and 6c). Figure 6a is a photograph showing lung tissue without Lewis lung carcinoma cell; Figure 6b, lung tissue implanted with Lewis lung carcinoma cell and then treated with PBS; and, Figure 6c, lung tissue implanted with Lewis lung carcinoma 20 cell and then treated with Saxatilin. As shown in Figures 6b and 6c, the metastatic tumor growth was observed in control group treated with PBS evidently(see: Figure 6b), while not observed in Saxatilin-administered group(see: Figure 6c). As illustrated as above, it was assumed that 25 the suppression of metastatic tumor growth in Saxatilin-treated mice was due to blockade of Saxatilin against angiogenesis, which was essential for the secondary tumor growth.

30 Administration and Effective Dose

35 The pharmaceutical composition of the present invention, which comprises an active ingredient of Saxatilin and pharmaceutically acceptable carrier may be administered as an injectable form. The injectable form may further comprise sterilized isotonic aqueous solution or suspension, and the pharmaceutically acceptable carrier

covers preservatives, stabilizers, wetting agents, emulsifiers, salts for changing osmotic pressure or buffers. Though the effective dose of Saxatilin is variable depending on age, body weight of the patient and 5 progression of the disease, it is preferable to administer parenterally 20 to 52mg/60kg/day in a single dose for the treatment of thrombosis, and 30 to 120mg/60kg/day in a single dose for the treatment of cancer, which may be individualized by experience of the skilled in the art.

10

Acute Toxicity

To examine the acute toxicity of Saxatilin as anti-platelet aggregation agent and anti-tumor agent, Saxatilin 15 was injected into male C57BL/6 mouse subcutaneously and the dead were counted to determine LD₅₀ for 7 days. As a result, LD₅₀ was determined as about 1100mg/kg, indicating that the anti-platelet aggregation agent and anti-tumor agent comprising Saxatilin were sufficiently safe within the 20 range of the effective dose.

As clearly illustrated and demonstrated as above, the present invention provides Saxatilin, a protein derived from the venom of a Korean snake, *Agkistrodon saxatilis emelianov*, a process for preparing the same, anti-platelet aggregation agent and anti-tumor agent comprising an active 25 ingredient of Saxatilin. The present inventors purified Saxatilin from the venom of *Agkistrodon saxatilis emelianov*, cloned cDNA encoding Saxatilin, and constructed a recombinant expression vector comprising the cDNA and a 30 recombinant microorganism transformed with the recombinant expression vector which expresses Saxatilin, and prepared Saxatilin by culturing the recombinant microorganism.

Saxatilin effectively suppresses the platelet aggregation and angiogenesis of tumor cells, which makes 35 possible its practical application as an active ingredient of anti-platelet agent and anti-tumor agent.

5 Although the preferred embodiments of the present invention have been disclosed for illustrative purpose, those who are skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as described in the accompanying claims.

10

15

20

25

30

35

**INDICATIONS RELATING TO DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**
(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in description On page <u>8</u> , line <u>37</u> to page <u>9</u> , line <u>6</u> .				
B. IDENTIFICATION OF DEPOSIT		Further deposits are identified on additional sheet		
Name of depositary institution Korean Culture Center of Microorganisms(KCCM)				
Address of depositary institution (including postal code and country) Korean Culture Center of Microorganisms(KCCM) 361-221, Yurim B/D, Hongje-1-dong, Seodaemun-gu Seoul, 120-091, Republic of Korea				
Date of deposit July 21, 2000		Accession Number KCCM-10201		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information continues on an additional sheet				
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)				
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)				
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")				

<p style="text-align: center;">For receiving Office use only</p> <p><input type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer</p>	<p style="text-align: center;">For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	---

WHAT IS CLAIMED IS:

1. cDNA represented as a nucleotide sequence of SEQ ID NO: 2, which codes for Saxatilin, a protein derived from 5 venom of *Agkistrodon saxatilis emelianov*.

2. Saxatilin represented as an amino acid sequence of SEQ ID NO: 1 which is derived from the cDNA of claim 1.

10 3. A process for preparing Saxatilin which comprises the steps of:

(i) gel filtration of venom collected from *Agkistrodon saxatilis emelianov* to obtain active fraction; and,

15 (ii) applying the active fraction to high performance liquid chromatography to purify Saxatilin.

20 4. An expression vector pPSAX containing the cDNA of claim 1.

25 5. A biologically pure culture of *Pichia pastoris* Y/pPSAX(KCCM-10201) which is obtained by transforming the expression vector pPSAX of claim 4 into *Pichia pastoris* GS115.

25 6. A process for preparing recombinant Saxatilin which comprises a step of culturing a microorganism transformed with an expression vector containing cDNA of claim 1 to obtain recombinant Saxatilin.

30 7. The process for preparing recombinant Saxatilin of claim 6, wherein the expression vector is pPSAX.

35 8. The process for preparing recombinant Saxatilin of claim 6, wherein the transformed microorganism is *Pichia pastoris* Y/pPSAX(KCCM-10201).

9. The process for preparing recombinant Saxatilin of claim 8, wherein the transformed microorganism is cultured under a condition of pH 5.5 to 6.5, 25 to 35°C for 12 to 24 hours, harvested by centrifugation and cultured 5 again on a medium containing 0.5 to 1.5%(v/v) methanol under a condition of pH 5.5 to 6.5, 25 to 35°C for 72 to 120 hours.

10. The process for preparing recombinant Saxatilin of claim 8, wherein the culture containing transformed 10 microorganism is subjected to a hydrophobic column and high performance liquid chromatography to purify Saxatilin.

11. Anti-platelet agent comprising an active 15 ingredient of Saxatilin and pharmaceutically acceptable carrier.

12. Anti-tumor agent comprising an active ingredient of Saxatilin and pharmaceutically acceptable carrier.

1/8




Fig. 1

2/8




Fig. 2

3/8




Fig. 3

4 / 8




Fig. 4a

5/8




Fig. 4b

6/8




Fig. 5a




Fig. 5b

7/8




Fig. 6a




Fig. 6b

8 / 8




Fig. 6c

1
SEQUENCE LISTING

5
<110> CHUNG, Kwang-Hoe

KIM, Doo-Sik

10
<120> Novel Protein Derived from Agkistrodon saxatilis emelianov

and Process for Preparing the Same

15
<160> 10

10
<170> KOPATIN 1.5

15
<210> 1

<211> 71

<212> PRT

20
<213> Agkistrodon saxatilis emelianov

<400> 1

Glu Ala Gly Glu Glu Cys Asp Cys Gly Ala Pro Ala Asn Pro Cys Cys

1 5 10 15

20
Asp Ala Ala Thr Cys Lys Leu Arg Pro Gly Ala Gln Cys Ala Glu Gly
20 25 30

25
Leu Cys Cys Asp Gln Cys Arg Phe Met Lys Glu Gly Thr Ile Cys Arg
35 40 45

30
Met Ala Arg Gly Asp Asp Met Asp Asp Tyr Cys Asn Gly Ile Ser Ala
50 55 60

35
Gly Cys Pro Arg Asn Pro Phe His Ala
65 70

<210> 2

<211> 213

<212> DNA

2
<213> Agkistrodon saxatilis emelianov

5
<400> 2
ggagaagaat gtgactgtgg cgctcctgca aatccgtgct gcgatgcgc aacctgaaa 60
ctgagaccag gggcgccagtg tgcagaagga ctgtgtgtg accagtgcag atttatgaaa 120
gaaggaacaa tatgccggat ggcaaggggt gatgacatgg atgattactg caatggcata 180

10 tctgctggct gtcccaaaaa tcccttccat gcc 213

15
<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

20
<220>
<223> primer

25
<400> 3
ggngargart gygaytgygg 20

30
<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

35
<220>
<223> primer

<400> 4
ggcatggaag ggatttctgg 20

3

<210> 5
<211> 33
<212> DNA
<213> Artificial Sequence

5

<220>
<223> primer

<400> 5

10 ccgctcgaga aaagagaggc cggagaagaa tgt 33

<210> 6
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

20

<400> 6
cggaattctc attaggcatg gaaggga 27

<210> 7
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> oligopeptide

<400> 7
Gly Arg²Gly Asp Ser Pro

1 5

35

4

<210> 8
<211> 6
<212> PRT
<213> Artificial Sequence

5

<220>
<223> oligopeptide

<400> 8
10 Gly Arg Gly Glu Thr Pro

1 5

<210> 9
<211> 12
15 <212> PRT
<213> Agkistrodon saxatilis emelianov

<400> 9
Gly Glu Glu Cys Asp Cys Gly Ala Pro Ala Asn Pro

20 1 5 10

<210> 10
<211> 73
25 <212> PRT
<213> Agkistrodon halys brevicaudus

<400> 10
Glu Ala Gly Glu Glu Cys Asp Cys Gly Ser Pro Gly Asn Pro Cys Cys

30 1 5 10 15

Asp Ala Ala Thr Cys Lys Leu Arg Gln Gly Ala Gln Cys Ala Glu Gly
20 25 30

35 Leu Cys Cys Asp Gln Cys Arg Phe Met Lys Glu Gly Thr Ile Cys Arg
35 40 45

5

Arg Ala Arg Gly Asp Asp Leu Asp Asp Tyr Cys Asn Gly Ile Ser Ala

50

55

60

5

Gly Cys Pro Arg Asn Pro Phe His Ala

65

70

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR00/00809

A. CLASSIFICATION OF SUBJECT MATTER

IPC7 C12N 15/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7 C12N, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean patents and applications for inventions since 1975

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

IPN, PAJ, Medline,

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KR 1997-006318 A (Mokam Biotech.) 19 Feb 1997 see the whole document	1-11
A	US 6,013,625 A (La Jolla Cancer Research Foundation) 11 Jan 2000 see the whole document	1-12
P,X	KOH YS et al., "Biochemical characterization of a thrombin-like enzyme and a fibrinolytic serine protease from snake (Agkistrodon saxatilis) venom." <i>Toxicon.</i> , Apr 2001;39(4) pages555-560. see the whole document	1-11
A	MATSUI T et al., "Purification and amino acid sequence of halystase from snake venom of Agkistrodon halys blomhoffii, a serine protease that cleaves specifically fibrinogen and kininogen" <i>Eur J Biochem.</i> , Mar 1998, 15;252(3), pages569-575. see the whole document	1-12

Further documents are listed in the continuation of Box C.

See patent family annex.

- * Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

28 MAY 2001 (28.05.2001)

Date of mailing of the international search report

30 MAY 2001 (30.05.2001)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
Government Complex-Daejeon, Dunsan-dong, Seo-gu, Daejeon
Metropolitan City 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

CHOI, Kyu Whan

Telephone No. 82-42-481-5595



INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR00/00809

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
KR 1997-006318 A	19.02.1997	None	
US 6,013,625 A	11.01.2000	None	